XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Dec. 31, 2023
Feb. 22, 2023
Feb. 21, 2023
Dec. 31, 2022
Collateralized debt obligations $ 1,870,517,000     $ 2,102,717,000
Common stock, par value (in dollars per share) $ 0.01     $ 0.01
Common stock, shares authorized (in shares) 200,000,000 200,000,000 800,000,000 200,000,000
Common stock, shares issued (in shares) 90,675,403     91,193,688
Common stock, shares outstanding (in shares) 90,675,403     91,193,688
Total assets [1] $ 7,401,328,000     $ 6,240,745,000
Total liabilities [1] 5,773,202,000     4,376,634,000
VIE, Primary Beneficiary        
Total assets 3,816,777,000     4,261,097,000
Total liabilities $ 3,076,818,000     $ 3,403,257,000
Preferred Stock Series Shares        
Preferred stock, par value (in dollars per share) $ 0.01     $ 0.01
Preferred stock, shares authorized (in shares) 31,500,000     31,500,000
Preferred stock, shares issued (in shares) 22,164,414     22,284,994
Preferred stock, shares outstanding (in shares) 22,164,414     22,284,994
Preferred Stock, aggregate liquidation preference $ 554,110,000     $ 557,125,000
Consolidated SLST CDOs        
Collateralized debt obligations 593,737,000     634,495,000
Consolidated SLST CDOs | VIE, Primary Beneficiary        
Collateralized debt obligations 593,737,000     634,495,000
Residential loan securitizations at amortized cost, net        
Collateralized debt obligations 1,276,780,000     1,468,222,000
Residential loan securitizations at amortized cost, net | VIE, Primary Beneficiary        
Collateralized debt obligations $ 1,276,780,000     $ 1,468,222,000
[1] Our consolidated balance sheets include assets and liabilities of consolidated variable interest entities (“VIEs”) as the Company is the primary beneficiary of these VIEs. As of December 31, 2023 and December 31, 2022, assets of consolidated VIEs totaled $3,816,777 and $4,261,097, respectively, and the liabilities of consolidated VIEs totaled $3,076,818 and $3,403,257, respectively. See Note 7 for further discussion.